CD37 and diffuse large B-cell lymphoma: Further observations revealed that CD37-negative DLBCL patients showed a significantly lower response and decreased survival after R-CHOP (rituximab+chemotherapy) treatment when compared to the CD37-positive population independently from CD20-status, International Prognostic Index (IPI), and cell of origin [47].